Hormonal cancer refers to any cancer whose growth is driven by the body’s own hormones, most commonly estrogen, progesterone, or testosterone. These cancers have receptors on their cells that bind to hormones the way a lock fits a key, and when that connection is made, the hormone signals the cancer cell to multiply. About 79% of breast cancers are hormone receptor-positive, making this one of the most common cancer classifications a patient will encounter on a pathology report.
The term isn’t a single disease. It’s a category that includes breast, prostate, ovarian, and endometrial cancers, all of which can depend on hormones to fuel their progression. Understanding whether a cancer is hormone-driven changes everything about how it’s treated.
How Hormones Drive Cancer Growth
Normal cells throughout your body have hormone receptors, proteins that pick up chemical signals from circulating hormones and use those signals to regulate growth, reproduction, and repair. In hormone-dependent cancers, this normal signaling process gets hijacked. The receptors still work, but now they’re telling a tumor cell to keep dividing.
In breast cancer, the process is well mapped. When estrogen binds to an estrogen receptor on a cancer cell, the receptor changes shape and pairs up with another receptor. That pair attaches to specific stretches of DNA inside the cell’s nucleus and switches on hundreds of genes involved in cell proliferation, survival, blood vessel formation, and even the ability to spread to other tissues. This isn’t a single rogue signal. It’s a coordinated program that touches nearly every aspect of how a tumor behaves.
The signaling can also happen indirectly. Growth factor receptors on the cell surface can activate the estrogen receptor from the outside, essentially turning it on even without estrogen present. This cross-talk between different signaling pathways is one reason some hormone-driven cancers eventually stop responding to treatments that target hormones alone.
In prostate cancer, testosterone and its more potent form (dihydrotestosterone) play the equivalent role. Most prostate cancers depend on the androgen receptor for growth, which is why blocking testosterone production is a cornerstone of treatment.
Which Cancers Are Hormone-Dependent
Breast and prostate cancers are by far the most common hormone-driven cancers, and they also happen to be the most common cancers overall in women and men. Ovarian cancer and endometrial (uterine lining) cancer round out the major hormone-dependent types, both influenced by estrogen and progesterone signaling.
Not every case of these cancers is hormone-dependent. In breast cancer, roughly 70% of tumors are hormone receptor-positive and HER2-negative, while another 9% are hormone receptor-positive and HER2-positive. That means about 4 in 5 breast cancer patients have tumors that respond to hormonal signals, based on national surveillance data from 2018 to 2022. The remaining cases lack hormone receptors entirely and require different treatment strategies. Prostate cancer skews even more heavily toward hormone dependence: the vast majority of prostate tumors rely on androgen receptor activity at the time of diagnosis.
How Hormone Status Is Determined
When a tumor is biopsied or surgically removed, pathologists test the tissue for hormone receptors using a staining technique called immunohistochemistry. This is considered the gold standard worldwide because it’s reliable, cost-effective, and works on preserved tissue samples. The pathologist applies a chemical stain that binds to estrogen receptors and progesterone receptors. If the stain lights up, the tumor is receptor-positive.
Results are reported in two ways: the percentage of cells that stain positive (called prevalence) and the intensity of that staining, graded as weak, intermediate, or strong. Some labs combine these into a composite number using scoring systems like the Allred score or H-score. In clinical practice, though, the staining percentage is the most commonly used measure. Current guidelines from the American Society of Clinical Oncology classify a tumor as hormone receptor-positive if more than 1% of cells show staining, though tumors with higher percentages tend to respond more strongly to hormone-blocking treatments.
Your pathology report will typically list ER (estrogen receptor) and PR (progesterone receptor) status for breast cancer, or note androgen receptor findings for prostate cancer. These results directly determine which treatments are on the table.
Why Hormone Status Affects Prognosis
Hormone receptor-positive cancers generally carry a better prognosis than receptor-negative cancers, at least in the first several years after diagnosis. In breast cancer, receptor-positive tumors have a slightly lower risk of recurrence in the first five years compared to receptor-negative tumors, and women with these cancers tend to have better survival over that period.
The reason is straightforward: if a cancer depends on hormones, you have an extra category of treatment available. You can cut off the fuel supply. Receptor-negative cancers don’t have that vulnerability, which limits treatment options to chemotherapy, radiation, and targeted therapies that work through other mechanisms.
There’s a caveat, though. Some hormone receptor-positive breast cancers can recur many years after initial treatment, sometimes a decade or more later, while receptor-negative cancers that don’t recur early tend to stay gone. This late recurrence risk is why some patients stay on hormone-blocking medication for five to ten years.
How Hormonal Cancers Are Treated
The central strategy for hormone-dependent cancer is to either block the hormone from reaching its receptor or stop the body from producing the hormone in the first place. In breast cancer, these two approaches map onto two major drug categories. One type works by physically blocking estrogen from binding to the receptor on the cancer cell. The other type shuts down estrogen production by disabling the enzyme that converts other hormones into estrogen, an approach that works in postmenopausal women whose ovaries are no longer the primary estrogen source.
For prostate cancer, the equivalent approach is called androgen deprivation therapy. The most common form uses drugs that suppress the brain’s signal to the testicles to produce testosterone. A second class of drugs blocks that signal through a slightly different mechanism. Surgical removal of the testicles achieves the same result permanently, though most patients today opt for medication. These treatments are typically the first line of hormone therapy for prostate cancer and can be combined with other drugs that block the androgen receptor directly.
Hormone therapy for cancer is not the same as hormone replacement therapy used for menopause symptoms. In fact, the two work in opposite directions: cancer hormone therapy suppresses hormone activity, while replacement therapy supplements it.
Risk Factors for Hormone-Driven Cancer
Anything that increases your lifetime exposure to hormones can raise the risk of developing a hormone-dependent cancer. Starting menstruation early, reaching menopause late, never having children, and having children later in life all extend the window of estrogen exposure for breast and uterine tissue.
Hormone replacement therapy during menopause has a nuanced relationship with breast cancer risk. NIH-funded research found that women taking estrogen-only hormone therapy actually had a 14% reduction in breast cancer incidence compared to women who never used it. But women taking combined estrogen-plus-progestin therapy experienced a 10% higher rate of breast cancer, rising to 18% higher among those who used the combination for more than two years. The type of hormone therapy matters significantly.
Obesity plays a role as well. Fat tissue produces estrogen, so carrying excess weight after menopause increases circulating estrogen levels at a time when ovarian production has stopped. This is one of the clearer links between body composition and cancer risk.
Environmental Hormone Disruptors
A growing body of evidence links synthetic chemicals in the environment to hormone-dependent cancers. These chemicals, called endocrine disruptors, can mimic estrogen or interfere with estrogen signaling pathways. The most studied include BPA (found in some plastics and can linings), DDT and other pesticides, and polychlorinated biphenyls (PCBs), industrial chemicals that persist in the environment long after being banned. These substances are sometimes called xenoestrogens because they act like estrogen in the body despite being foreign chemicals. They are widespread in agriculture, consumer products, and industrial settings, and researchers believe they play a meaningful role in the rising incidence of breast cancer across many countries.